Dihexa Acetate

Dihexa Acetate is the acetate salt form of Dihexa, an orally active oligopeptide derived from angiotensin IV that binds hepatocyte growth factor to potentiate c-Met signaling, promoting synaptogenesis, neuroplasticity, and cognitive enhancement.

Brief glance

The primary outcome is Cognitive. This compound is considered a Small Molecule. It is not currently indicated as compoundable in 503A pharmacies. It is not listed under a DEA schedule.

Overview

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at the c-Met receptor. This compound promotes neuroplasticity, synaptogenesis, and cognitive enhancement by facilitating new synaptic connections and crossing the blood-brain barrier effectively. Originally researched for Alzheimer's disease and neurodegenerative conditions, Dihexa shows promise in improving memory and learning in preclinical models.

Dihexa acetate, known chemically as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is an orally active oligopeptide derived from angiotensin IV that crosses the blood-brain barrier to bind hepatocyte growth factor (HGF) with high affinity and potentiate its activity at the c-Met receptor. This mechanism promotes synaptogenesis, enhances neuroplasticity, and supports neuronal survival, making it vastly more potent than brain-derived neurotrophic factor in neurotrophic assays—seven orders of magnitude superior. Originally developed at Washington State University for cognitive enhancement, Dihexa has demonstrated potent improvements in cognitive function and synaptic density in animal models of Alzheimer's disease and related impairments. Short-term safety studies indicate no apparent toxicity or neoplastic risks despite c-Met's oncogene status. While preclinical data are promising, human clinical trials remain limited.

Benefits

Dihexa Acetate promotes synaptogenesis, demonstrating potency up to one million times greater than brain-derived neurotrophic factor (BDNF) in preclinical models, which supports enhanced memory formation, learning, and cognitive recovery.¹,²,³,⁴,⁵ In animal studies of Alzheimer's disease, it restores spatial learning, reduces neuroinflammation by decreasing pro-inflammatory cytokines like IL-1β and TNF-α while increasing anti-inflammatory IL-10, and increases neuronal cells and synaptic protein expression.³,⁶ It shows potential for reversing cognitive impairment in models of neurodegeneration, traumatic brain injury, and stroke by fostering neuroplasticity and neuroprotection, though human clinical trials remain lacking.¹,²,⁴,⁷ Short-term safety data indicate no apparent toxicity or neoplastic effects in preclinical assessments.⁵

Side effects

Potential side effects of Dihexa Acetate include mild nervousness, irritability, headaches, anxiety, overstimulation, temporary insomnia, bleeding problems such as easy bruising or nosebleeds, and allergic reactions like rash, hives, fever, or swelling of the face, lips, or throat.³,⁷,⁸ It is generally well-tolerated at recommended doses with a low toxicity profile and no apparent short-term toxicity observed in preliminary studies, though data remains limited.⁴,⁵,⁸ Key safety considerations involve its activation of HGF/c-Met signaling, raising theoretical risks of tumorigenesis or cancer progression, particularly in patients with active cancers or malignancy history, and its long half-life necessitating caution for long-term use.²,⁴ Pregnant or breastfeeding individuals, those with sensitivities to nootropics or peptides, and anyone planning extended use should avoid it or consult a healthcare provider due to the absence of human clinical trials and long-term safety data.⁴,⁸ More research is required to fully characterize risks.³,⁴

Mechanisms of action

Dihexa binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at the c-Met receptor on neurons⁵,⁹. This binding activates c-Met phosphorylation, which triggers a cascade of intracellular signaling events that stimulate synaptogenesis—the formation of new synaptic connections between neurons³,¹⁰. The compound also promotes dendritic spine formation and enhances synaptic density in brain regions associated with learning and memory, while reducing neuroinflammatory signaling through modulation of the PI3K/AKT pathway⁶,¹⁰. Unlike conventional cognitive agents that work primarily through neurotransmitter modulation with temporary effects, dihexa produces structural changes to neural architecture by acting as an HGF mimetic¹⁰. Preclinical studies have demonstrated that dihexa is remarkably potent, with neurotrophic activity seven orders of magnitude greater than brain-derived neurotrophic factor, and it crosses the blood-brain barrier to exert direct action on central nervous system tissue⁵.